Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Francesco Panza, Madia Lozupone, Davide Seripa, Bruno P Imbimbo

Research output: Contribution to journalReview articlepeer-review


The amyloid-β (Aβ) cascade hypothesis of Alzheimer disease (AD) holds that brain accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted Aβ production, clearance, and deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early, or prodromal disease, or in those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aβ forms are undergoing large-scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aβ suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease. ANN NEUROL 2019;85:303-315.

Original languageEnglish
Pages (from-to)303-315
Number of pages13
JournalAnnals of Neurology
Issue number3
Publication statusPublished - Mar 2019


  • Alzheimer Disease/drug therapy
  • Amyloid beta-Peptides/metabolism
  • Antibodies, Monoclonal/therapeutic use
  • Brain/metabolism
  • Drug Development
  • Humans
  • Immunotherapy
  • Molecular Targeted Therapy


Dive into the research topics of 'Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?'. Together they form a unique fingerprint.

Cite this